Betsy Wonderly Trainor
Betsy Wonderly Trainor leads the diagnostics program at CARB-X, a global non-profit dedicated to addressing the health threat of drug-resistant bacteria. Throughout her career, Betsy has focused on the development and commercialization of In-Vitro Diagnostics for viral and bacterial detection, globally. Prior to managing the CARB-X diagnostic portfolio, Betsy led the clinical studies for multiple IVDs throughout Africa, the commercialization of a variety of IVD product lines, globally, and strategic partnerships on behalf of both private and public entities. She has supported the development of target product profiles and global guidelines and negotiated deals with large donor organizations and industry. She has supported development efforts at multiple innovative companies, including Daktari Diagnostics, Aldatu Biosciences, SystemOne, and Dimagi, in addition to leading product validation and implementation efforts at the Foundation for Innovative New Diagnostics (FIND) and the World Health Organization (WHO). With a range of experience in the areas of pandemic response, diagnostic development, and data management, her research and commentary have been published in academic journals, including BMJ Global Health, Journal of Clinical Microbiology, The Lancet, and PLoS One. Betsy currently serves on the Advisory Panel for the Longitude Prize focused on AMR and she represents CARB-X in the ValueDx Consortium. She served as co-chair of the National Academy of Sciences Workshop — Accelerating the Development and Uptake of Rapid Diagnostics to Address Antibiotic Resistance — and is deeply interested in policy changes that may enable a healthier market for AMR-focused diagnostics. Betsy has an interdisciplinary background in behavioral and clinical research and business. She holds a BS in Human Development form Cornell University and has completed executive education training at the University of California, Berkeley, Haas School of Business.